Procarbazine
Information
- Drug Name
- Procarbazine
- Description
- Entry(CIViC)
- 1
CIViC
| Disease | Mutation | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| malignant astrocytoma |
ATRX UNDEREXPRESSION ( ENST00000373344.11 ) ATRX UNDEREXPRESSION ( ENST00000373344.11 ) |
B |
Predictive
|
Supports
|
N/A
|
3 | 23904111 | Detail |
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| A retrospective tumor sample study found that the ... | ATRX |
ATRX UNDEREXPRESSION ( ENST00000373344.11 ) ATRX UNDEREXPRESSION ( ENST00000373344.11 ) |
N/A | true | CIViC Evidence | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05008224 | Active, not recruiting | Phase 2 | Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11) | October 7, 2021 | May 22, 2024 |
| NCT02661503 | Active, not recruiting | Phase 3 | HD21 for Advanced Stages | July 2016 | September 2025 |
| NCT00577993 | Completed | Phase 3 | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | March 16, 1998 | August 24, 2017 |
| NCT01399372 | Completed | Phase 2 | Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma | September 2011 | May 20, 2022 |
| NCT00265031 | Completed | Phase 3 | HD12 for Advanced Stages | January 1999 | |
| NCT01251107 | Completed | Phase 3 | Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma | March 2000 | November 2009 |
| NCT00264953 | Completed | Phase 3 | HD11 for Intermediate Stages | May 1998 | |
| NCT01569204 | Completed | Phase 2 | Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma | October 2012 | December 2017 |
| NCT02298283 | Completed | Phase 2 | Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD | April 2015 | July 9, 2020 |
| NCT00887146 | Recruiting | Phase 3 | Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma | September 2009 | October 2025 |
| NCT03495960 | Recruiting | Phase 2 | Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System | June 15, 2019 | December 31, 2024 |
| NCT02315326 | Recruiting | Phase 1/Phase 2 | Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL) | December 2014 | December 2026 |
| NCT01390584 | Terminated | Phase 2 | Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma | May 24, 2013 | May 18, 2018 |
| NCT00335140 | Terminated | Phase 2 | Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma | August 23, 2007 | July 2015 |
| NCT00989352 | Unknown status | Phase 2 | Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma | September 2009 | September 2011 |
| NCT01468740 | Unknown status | Phase 2 | Prospective Study on HIV-related Hodgkin Lymphoma | March 2004 | July 2012 |